Contrasting ProKidney (NASDAQ:PROK) and CytomX Therapeutics (NASDAQ:CTMX)

ProKidney (NASDAQ:PROK) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Volatility & Risk

ProKidney has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.

Profitability

This table compares ProKidney and CytomX Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Institutional and Insider Ownership

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 39.8% of ProKidney shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares ProKidney and CytomX Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890,000.00	489.15	-$68.99 million	($0.55)	-2.62
CytomX Therapeutics	$76.20 million	7.18	-$17.37 million	($0.50)	-5.02

CytomX Therapeutics has higher revenue and earnings than ProKidney. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ProKidney and CytomX Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1	0	1	1	2.67
CytomX Therapeutics	1	1	9	1	2.83

ProKidney currently has a consensus price target of $12.00, suggesting a potential upside of 733.33%. CytomX Therapeutics has a consensus price target of $11.90, suggesting a potential upside of 374.10%. Given ProKidney’s higher probable upside, equities analysts plainly believe ProKidney is more favorable than CytomX Therapeutics.

Summary

CytomX Therapeutics beats ProKidney on 8 of the 14 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About CytomX Therapeutics

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.